Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Akebia Therapeutics (AKBA) Short-Term Debt repayments (2019)

Akebia Therapeutics has reported Short-Term Debt repayments over the past 1 years, most recently at $15.0 million for Q1 2019.

Quarterly Short-Term Debt repayments changed N/A to $15.0 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2019, changed N/A year-over-year, with the annual reading at $32.0 million for FY2023, 3.03% down from the prior year.
Short-Term Debt repayments was $15.0 million for Q1 2019 at Akebia Therapeutics.
Over five years, Short-Term Debt repayments peaked at $15.0 million in Q1 2019 and troughed at $15.0 million in Q1 2019.